Devon Cayer is the founder of 1859. 1859 has raised $40M in total funding. Latest round: Series A. Based in San Diego, United States.
Devon Cayer is a co-founder of 1859, a biotechnology company established in 2019 in San Diego, California. The company accelerates early-stage drug discovery by integrating artificial intelligence with high-throughput empirical screening, specifically using a proprietary platform to test custom chemical compound libraries. 1859 emerged from stealth mode in 2022 with a $40 million Series A funding round. Cayer, who initially served as CEO, brought expertise from The Scripps Research Institute where he invented DNA barcoding technologies, and prior experience at Omniome and Singular Genomics.
Full founder directory · Investor directory · Company funding database · Fundraising library